Beijing May Prioritize Consumers in the Year of the Horse: Strategies to Consider.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 15 2026
0mins
Source: Barron's
- Economic Outlook: As China enters the Year of the Fire Horse, there is an expectation of a lower official economic growth target from Beijing.
- Focus Shift: The Chinese government is anticipated to prioritize reviving consumer confidence and spending over previous economic strategies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 903.020
Low
950.00
Averages
1192
High
1500
Current: 903.020
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ELI LILLY: DEAL ANTICIPATED TO FINALIZE IN LATE 2026
- Transaction Closure: A transaction is expected to close in the second half of 2026.
- Future Outlook: The timeline indicates a significant event or change anticipated in the near future.
See More
ELI LILLY TO ACQUIRE KELONIA; SHAREHOLDERS TO RECEIVE UP TO $7 BILLION IN CASH UNDER AGREEMENT TERMS
- Acquisition Announcement: Lilly will acquire Kelonia under the terms of an agreement.
- Financial Details: Kelonia shareholders are set to receive up to $7.00 billion in cash.
See More
LILLY SET TO PURCHASE KELONIA THERAPEUTICS TO FURTHER DEVELOP IN VIVO CAR-T CELL THERAPIES
Acquisition Announcement: LILLY has announced its acquisition of KELONIA, a company specializing in advanced therapeutic solutions.
Focus on In Vivo CAR-T Cell Therapies: The acquisition aims to enhance LILLY's capabilities in developing in vivo CAR-T cell therapies, which are innovative treatments for various diseases.
See More
Roche Reports 5% Sales Decline in Q1 Amid Currency Pressures
- Sales Performance Decline: Roche reported first-quarter sales of 14.7 billion Swiss francs ($18.7 billion), a 5% year-on-year decline, primarily impacted by the strength of the Swiss franc and competition from generics for older drugs, indicating pressure on the company's market position.
- Significant Currency Impact: While sales in Swiss francs decreased, there was a 6% increase in constant currency terms, highlighting the substantial effect of currency fluctuations, particularly as the Swiss franc appreciated against the U.S. dollar, leading to a 9% increase in dollar-denominated sales.
- Future Investment Strategy: CEO Thomas Schinecker stated that Roche will continue to invest in the U.S. market and plans to enhance its market position through acquisitions, demonstrating confidence in future growth despite pressures from expiring patents on older drugs.
- Weight Loss Market Positioning: Roche is actively positioning itself in the weight loss market, aiming to become a top-three player with its experimental drug CT-388, targeting a double-digit market share in the future, indicating a strategic focus on emerging markets.
See More
Rapid Growth of Hybrid Vehicle Market in India
- Surge in Hybrid Sales: According to a report by Care Ratings, hybrid vehicle sales in India reached 362,866 units in the financial year ending March 2026, up nearly fourfold from 98,010 units in 2020, indicating a strong consumer demand for better fuel efficiency, with hybrids expected to account for 10% of total car sales by FY2027.
- Limited EV Market Share: Despite the rising demand for electric vehicles, only 131,865 units are projected to be sold by March 2026, reflecting a consumer preference for hybrids due to concerns over inadequate charging infrastructure.
- Market Leaders: Toyota and Maruti Suzuki dominate the hybrid vehicle market in India, with Toyota selling 366,896 cars including 91,536 strong hybrids in FY2026, while Maruti sold 20,466 strong hybrids, further solidifying their market positions.
- Future Model Launches: Experts predict that more hybrid models will be launched in the next 12 months than in the past five years combined, driven by increasing consumer acceptance of hybrids that require no change in refueling habits, thereby propelling market growth.
See More
Eli Lilly Stock Valuation Analysis
- Psychological Price Barrier: Eli Lilly's current share price of $903 is perceived as a psychological barrier; while many investors focus on absolute prices, true valuation should consider the earnings generated per dollar invested, indicating that the stock may be reasonably valued.
- Diversified Pipeline Advantage: Lilly's revenue and earnings outlook are heavily influenced by the rapid adoption of its dual GIP/GLP-1 agonists, Mounjaro and Zepbound, while its anti-amyloid antibody, Kisunla, and dermatology and immunology programs further diversify its portfolio, reducing the risk associated with reliance on a single product.
- Forward Earnings Multiple Discount: Despite the expansion of Lilly's product portfolio, its current forward P/E ratio remains significantly lower than the euphoric peaks of the initial GLP-1 hype cycle, suggesting that investors are paying less for expected future earnings compared to a few years ago, reflecting a lack of market recognition for its diversified business.
- Long-Term Investment Opportunity: As new drugs transition from clinical promise to billion-dollar commercial realities, Lilly's earnings base is set to expand, leading to a potential re-rating of its valuation multiples, making the current price of $925 an attractive entry point for long-term investors.
See More
ELI LILLY: DEAL ANTICIPATED TO FINALIZE IN LATE 2026
- Transaction Closure: A transaction is expected to close in the second half of 2026.
- Future Outlook: The timeline indicates a significant event or change anticipated in the near future.
See More
ELI LILLY TO ACQUIRE KELONIA; SHAREHOLDERS TO RECEIVE UP TO $7 BILLION IN CASH UNDER AGREEMENT TERMS
- Acquisition Announcement: Lilly will acquire Kelonia under the terms of an agreement.
- Financial Details: Kelonia shareholders are set to receive up to $7.00 billion in cash.
See More
LILLY SET TO PURCHASE KELONIA THERAPEUTICS TO FURTHER DEVELOP IN VIVO CAR-T CELL THERAPIES
Acquisition Announcement: LILLY has announced its acquisition of KELONIA, a company specializing in advanced therapeutic solutions.
Focus on In Vivo CAR-T Cell Therapies: The acquisition aims to enhance LILLY's capabilities in developing in vivo CAR-T cell therapies, which are innovative treatments for various diseases.
See More
Roche Reports 5% Sales Decline in Q1 Amid Currency Pressures
- Sales Performance Decline: Roche reported first-quarter sales of 14.7 billion Swiss francs ($18.7 billion), a 5% year-on-year decline, primarily impacted by the strength of the Swiss franc and competition from generics for older drugs, indicating pressure on the company's market position.
- Significant Currency Impact: While sales in Swiss francs decreased, there was a 6% increase in constant currency terms, highlighting the substantial effect of currency fluctuations, particularly as the Swiss franc appreciated against the U.S. dollar, leading to a 9% increase in dollar-denominated sales.
- Future Investment Strategy: CEO Thomas Schinecker stated that Roche will continue to invest in the U.S. market and plans to enhance its market position through acquisitions, demonstrating confidence in future growth despite pressures from expiring patents on older drugs.
- Weight Loss Market Positioning: Roche is actively positioning itself in the weight loss market, aiming to become a top-three player with its experimental drug CT-388, targeting a double-digit market share in the future, indicating a strategic focus on emerging markets.
See More
Rapid Growth of Hybrid Vehicle Market in India
- Surge in Hybrid Sales: According to a report by Care Ratings, hybrid vehicle sales in India reached 362,866 units in the financial year ending March 2026, up nearly fourfold from 98,010 units in 2020, indicating a strong consumer demand for better fuel efficiency, with hybrids expected to account for 10% of total car sales by FY2027.
- Limited EV Market Share: Despite the rising demand for electric vehicles, only 131,865 units are projected to be sold by March 2026, reflecting a consumer preference for hybrids due to concerns over inadequate charging infrastructure.
- Market Leaders: Toyota and Maruti Suzuki dominate the hybrid vehicle market in India, with Toyota selling 366,896 cars including 91,536 strong hybrids in FY2026, while Maruti sold 20,466 strong hybrids, further solidifying their market positions.
- Future Model Launches: Experts predict that more hybrid models will be launched in the next 12 months than in the past five years combined, driven by increasing consumer acceptance of hybrids that require no change in refueling habits, thereby propelling market growth.
See More
Eli Lilly Stock Valuation Analysis
- Psychological Price Barrier: Eli Lilly's current share price of $903 is perceived as a psychological barrier; while many investors focus on absolute prices, true valuation should consider the earnings generated per dollar invested, indicating that the stock may be reasonably valued.
- Diversified Pipeline Advantage: Lilly's revenue and earnings outlook are heavily influenced by the rapid adoption of its dual GIP/GLP-1 agonists, Mounjaro and Zepbound, while its anti-amyloid antibody, Kisunla, and dermatology and immunology programs further diversify its portfolio, reducing the risk associated with reliance on a single product.
- Forward Earnings Multiple Discount: Despite the expansion of Lilly's product portfolio, its current forward P/E ratio remains significantly lower than the euphoric peaks of the initial GLP-1 hype cycle, suggesting that investors are paying less for expected future earnings compared to a few years ago, reflecting a lack of market recognition for its diversified business.
- Long-Term Investment Opportunity: As new drugs transition from clinical promise to billion-dollar commercial realities, Lilly's earnings base is set to expand, leading to a potential re-rating of its valuation multiples, making the current price of $925 an attractive entry point for long-term investors.
See More
